Print

Purpose

This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.

Condition

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Laboratory values meet the criteria specified in the protocol. - A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).

Exclusion Criteria

  • History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug. - Chronic recurring infection and/or active viral infection. - Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study drug administration. - Use of tobacco or nicotine-containing products within 90 days prior to the first dose of study drug. - Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix. - History or evidence of active tuberculosis (TB) disease or latent TB infection - Prior exposure to ABBV-722 within 90 days prior to the first dose of study drug.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Period 1: Group 1 		Participants will receive multiple doses of Upadacitinib
  • Drug: Upadacitinib
    Oral
Experimental
Period 1: Group 2 		Participants will receive multiple doses of Upadacitinib
  • Drug: Upadacitinib
    Oral
Experimental
Period 2: Group 1 		Participants will receive multiple doses of ABBV-722
  • Drug: ABBV-722
    Oral
Experimental
Period 2: Group 2 		Participants will receive multiple doses of ABBV-722
  • Drug: ABBV-722
    Oral
Experimental
Period 3: Group 1 		Participants will receive multiple doses of ABBV-722 and Upadacitinib
  • Drug: ABBV-722
    Oral
  • Drug: Upadacitinib
    Oral
Experimental
Period 3: Group 2 		Participants will receive multiple doses of ABBV-722 and Upadacitinib
  • Drug: ABBV-722
    Oral
  • Drug: Upadacitinib
    Oral

Recruiting Locations

Acpru /Id# 279285
Grayslake, Illinois 60030

More Details

Status
Recruiting
Sponsor
AbbVie

Study Contact

ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.